Vascular Toxicity of Antineoplastic Agents Ravi K. Bobba Donald C. Doll The association of venous thromboembolism (VTE) with underlying malignancy is well known; thereby screening for an occult malignancy in…
Chemotherapy-Induced Peripheral Neuropathy Frederick Hausheer Stacey Bain Chemotherapy-induced peripheral neuropathy (CIPN) is a common and serious clinical problem that affects many patients receiving cancer treatment.1,2,3,4 This iatrogenic condition can pose…
Chemotherapy-Induced Renal and Electrolyte Dysfunction Harbaksh Sangha Ramesh Khanna The chemotherapeutic drugs that are filtered, secreted, and cleared by the kidneys have the potential to cause acute and chronic kidney…
Hepatotoxicity of Chemotherapeutic Agents Ravi K. Bobba Stephen Medlin Michael C. Perry The development of abnormal liver function tests (LFTs) in a patient who is receiving chemotherapy can present a…
Gastrointestinal Complications of Chemotherapy Rashmi Ramasubbaiah Gastrointestinal (GI) side effects are very common with most chemotherapeutic and targeted agents (biologics). Most experts feel that the toxicities are generally underreported.1,2,3 It…
Pulmonary Toxicity of Chemotherapeutic Agents Vamsi P. Guntur Rajiv Dhand Pulmonary toxicity is recognized with a growing number of chemotherapeutic agents. An estimated 5% to 20% or more of patients…
Cardiotoxicity of Cancer Therapy Justin D. Floyd Michael C. Perry It is well recognized that antineoplastic agents may have adverse effects on multiple organs and normal tissues. The most commonly…
Ocular Side Effects of Cancer Therapeutics Ravi Bobba Mark Klein The increased use of chemotherapeutic agents combined with longer patient survival has led to a higher incidence and recognition of…
Hypersensitivity Reactions C. Daniel Kingsley Nearly all of the available chemotherapeutic agents can produce hypersensitivity reactions (HSRs) in at least an occasional patient, and some cause reactions in 5% or…
Extravasation Taher Abu Hejleh Gerald H. Clamon The accidental extravasation of chemotherapeutic agents during intravenous administration has been reported in approximately 0.1% to 6.0% of patients.1,2 Cancer patients may be…
